This study looks at two treatments for certain types of lymphoma, a kind of cancer that affects the immune system. **Zanubrutinib** is a drug that stops cancer cells from growing, and **Anti-CD20** drugs are medications that target specific cancer cells. **Lenalidomide** is a medication that helps the immune system fight cancer, and **Rituximab** is another drug that targets cancer cells. The study checks which combination works better for people whose lymphoma has come back or didn't respond to treatment. The main goal is to see how long the patients stay free from cancer getting worse, using special imaging tests like PET/CT and CT scans.

• Participants need to have had at least one previous treatment for lymphoma.
• The study involves comparing two drug combinations over time to see which one is more effective.
• Patients will be monitored for their progression-free survival, which means how long they stay without cancer getting worse.